In similarity to clinically approved SNIs (i.e. alpelisib, everolimus and capivasertib) inavolisib, RLY-2608 and STX-478 showed only limited ability to inhibit PI3K/AKT/mTOR pathway signalling in breast and endometrial cancer cells (Fig. 2a, b). This evidence concerns the gene PIK3CG and endometrial cancer.